drugset / Trial / NCT00072618

Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

NCT00072618

Phase 1/2 Completed 52 enrolled Astellas Pharma Inc OSI Pharmaceuticals · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if the combination of Taxotere and exisulind is an effective and safe treatment for patients with advanced NSCLC who have failed a prior platinum-containing regimen.

Timeline

Start
2001-10
Primary completion
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Exisulind Small molecule